2025 saw clinical and financial progress in key portfolio companies, but persistent market volatility and capital constraints led to a net loss and reduced liquidity. Continued operations depend on securing additional financing in 2026, with long-term prospects tied to portfolio performance.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.